In:
Cancer Science, Wiley, Vol. 109, No. 9 ( 2018-09), p. 2830-2840
Abstract:
Although induction immunochemotherapy including high‐dose cytarabine and rituximab followed by high‐dose chemotherapy ( HDC ) with autologous stem cell transplantation ( ASCT ) is recommended for younger patients (≤65 years old) with untreated mantle cell lymphoma ( MCL ), no standard induction and HDC regimen has been established. We conducted a phase II study of induction immunochemotherapy of R‐High‐ CHOP / CHASER followed by HDC of LEED with ASCT in younger patients with untreated advanced MCL . Eligibility criteria included untreated MCL , stage II bulky to IV , and age 20‐65 years. Patients received 1 cycle of R‐High‐ CHOP followed by 3 cycles of CHASER every 3 weeks. Peripheral blood stem cells ( PBSC ) were harvested during CHASER . LEED with ASCT was delivered to patients who responded to R‐High‐ CHOP / CHASER . Primary endpoint was 2‐year progression‐free survival ( PFS ). From June 2008 to June 2012, 45 patients (median age 59 years; range 38‐65 years) were enrolled. PBSC were successfully harvested from 36 of 43 patients. Thirty‐five patients completed ASCT . Two‐year PFS was 77% (80% CI 68‐84), which met the primary endpoint. Five‐year PFS and overall survival were 52% (95% CI 34‐68%) and 71% (95% CI 51‐84%), respectively. Overall response and complete response rates after induction immunochemotherapy were 96% and 82%, respectively. The most common grade 4 toxicities were hematological. In younger patients with untreated MCL , R‐High‐ CHOP / CHASER / LEED with ASCT showed high efficacy and acceptable toxicity, and it can now be considered a standard treatment option.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2018.109.issue-9
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink